104 related articles for article (PubMed ID: 30931254)
1. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
Svensson MC; Borg D; Zhang C; Hedner C; Nodin B; Uhlén M; Mardinoglu A; Leandersson K; Jirström K
Front Oncol; 2019; 9():136. PubMed ID: 30931254
[No Abstract] [Full Text] [Related]
2. Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment.
Kawatoko S; Kohashi K; Torisu T; Sasaki T; Umekita S; Oki E; Nakamura M; Kitazono T; Oda Y
Pathol Res Pract; 2022 Oct; 238():154124. PubMed ID: 36137397
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status.
Valentini AM; Di Pinto F; Coletta S; Guerra V; Armentano R; Caruso ML
Oncol Lett; 2019 Aug; 18(2):1775-1785. PubMed ID: 31423245
[TBL] [Abstract][Full Text] [Related]
4. DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer.
Guo F; Lu R; Kong W; Anwar M; Feng Y
Cancer Cell Int; 2024 Jan; 24(1):25. PubMed ID: 38200495
[TBL] [Abstract][Full Text] [Related]
5. MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer.
Momose K; Yamasaki M; Tanaka K; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncol Lett; 2017 Jul; 14(1):958-964. PubMed ID: 28693258
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint markers and tumour mutation burden in Wilms tumour: a study of 59 cases.
Mattis AJ; Chen JF; Gonzalez IA; Rais R; Dehner LP; Pfeifer J; He M
Pathology; 2024 May; ():. PubMed ID: 38879422
[TBL] [Abstract][Full Text] [Related]
7. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
Okadome K; Baba Y; Nomoto D; Yagi T; Kalikawe R; Harada K; Hiyoshi Y; Nagai Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Shono T; Sasaki Y; Baba H
Br J Cancer; 2020 May; 122(10):1535-1543. PubMed ID: 32210369
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
10. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer.
Oliveira AF; Bretes L; Furtado I
Front Oncol; 2019; 9():396. PubMed ID: 31139574
[TBL] [Abstract][Full Text] [Related]
11. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Christina Svensson M; Lindén A; Nygaard J; Borg D; Hedner C; Nodin B; Leandersson K; Jirström K
Oncoimmunology; 2021 May; 10(1):1921443. PubMed ID: 34104541
[TBL] [Abstract][Full Text] [Related]
12. Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma.
Coimbra BC; Pereira MA; Cardili L; Alves VAF; de Mello ES; Ribeiro U; Ramos MFKP
World J Gastrointest Oncol; 2024 Mar; 16(3):883-893. PubMed ID: 38577458
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma.
Papadakos KS; Gorji-Bahri G; Gialeli C; Hedner C; Hagerling C; Svensson MC; Jeremiasen M; Borg D; Fristedt R; Jirström K; Blom AM
Cancer Immunol Immunother; 2024 Apr; 73(5):93. PubMed ID: 38563861
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis.
Chen XJ; Wei CZ; Lin J; Zhang RP; Chen GM; Li YF; Nie RC; Chen YM
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509642
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 testing in advanced gastric cancer-what physicians who treat this disease must know-a literature review.
Peixoto RD; Mathias-Machado MC; Jácome A; Gil M; Fogacci J; Sodré B; Passarini T; Chaves A; Diniz PH; Lino F; Palladino A; Souto M; de Castro AC; Garicochea B
J Gastrointest Oncol; 2023 Jun; 14(3):1560-1575. PubMed ID: 37435200
[TBL] [Abstract][Full Text] [Related]
16. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers.
Mezheyeuski A; Backman M; Mattsson J; Martín-Bernabé A; Larsson C; Hrynchyk I; Hammarström K; Ström S; Ekström J; Mauchanski S; Khelashvili S; Lindberg A; Agnarsdóttir M; Edqvist PH; Huvila J; Segersten U; Malmström PU; Botling J; Nodin B; Hedner C; Borg D; Brändstedt J; Sartor H; Leandersson K; Glimelius B; Portyanko A; Ponten F; Jirström K; Micke P; Sjöblom T
EBioMedicine; 2023 Feb; 88():104452. PubMed ID: 36724681
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis.
Ren J; He Q; Yin H; Zheng L; Li L; Wu X
Clin Transl Oncol; 2023 May; 25(5):1436-1445. PubMed ID: 36528835
[TBL] [Abstract][Full Text] [Related]
18. CT-based radiomic nomogram for preoperative prediction of DNA mismatch repair deficiency in gastric cancer.
Zeng Q; Zhu Y; Li L; Feng Z; Shu X; Wu A; Luo L; Cao Y; Tu Y; Xiong J; Zhou F; Li Z
Front Oncol; 2022; 12():883109. PubMed ID: 36185292
[TBL] [Abstract][Full Text] [Related]
19. PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma.
Jiang D; Song Q; Wei X; Yu Z; Liu Y; Wang H; Wang X; Huang J; Su J; Hong Y; Xu Y; Xu C; Hou Y
Front Oncol; 2022; 12():897527. PubMed ID: 35865481
[TBL] [Abstract][Full Text] [Related]
20. Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue.
Sommer U; Ebersbach C; Beier AK; Baretton GB; Thomas C; Borkowetz A; Erb HHH
Front Mol Biosci; 2022; 9():878353. PubMed ID: 35836932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
